BRAIN Biotech AG Stock price

Equities

BNN

DE0005203947

Environmental Services & Equipment

Real-time Estimate Tradegate 11:58:30 2024-03-28 am EDT 5-day change 1st Jan Change
3.625 EUR +6.62% Intraday chart for BRAIN Biotech AG -10.85% -5.74%
Sales 2024 * 64.79M 69.91M Sales 2025 * 75.94M 81.95M Capitalization 74.28M 80.16M
Net income 2024 * -5M -5.4M Net income 2025 * -2M -2.16M EV / Sales 2024 * 1.52 x
Net Debt 2024 * 24.4M 26.33M Net Debt 2025 * 22.75M 24.55M EV / Sales 2025 * 1.28 x
P/E ratio 2024 *
-20.4 x
P/E ratio 2025 *
-25 x
Employees 311
Yield 2024 *
-
Yield 2025 *
-
Free-Float 39.38%
More Fundamentals * Assessed data
Dynamic Chart
BRAIN Biotech AG and AMSilk GmbH Announce the Successful Completion of the First Phase of A Development Collaboration CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2023 CI
BRAIN Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Transcript : BRAIN Biotech AG, Q2 2023 Earnings Call, May 25, 2023
BRAIN Biotech to Look Acquisitions CI
BRAIN Biotech AG acquired remaining 17.8% stake in Biocatalysts Limited. CI
SolasCure Limited announced that it has received £10.9 million in funding from Seneca Partners Limited, BRAIN Biotech AG, Eva Pharma Consultants Ltd, Wealth Club Limited and another investor CI
BRAIN Biotech AG announced that it expects to receive ?5 million in funding from MP Beteiligungs-Gmbh CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
BRAIN Biotech Ends Contract with Roquette Frères on Natural Sweetener Joint Development MT
BRAIN Biotech Unit to Focus on Developing New Therapies Via Genome-editing Technology MT
BRAIN Biotech AG Announces Executive Changes CI
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2022 CI
More news
1 day+5.00%
1 week-9.82%
Current month-10.74%
1 month-12.75%
3 months-7.18%
6 months-17.88%
Current year-4.64%
More quotes
1 week
3.36
Extreme 3.36
3.90
1 month
3.36
Extreme 3.36
4.04
Current year
3.23
Extreme 3.23
4.19
1 year
3.21
Extreme 3.21
6.26
3 years
3.21
Extreme 3.21
11.00
5 years
3.21
Extreme 3.21
14.28
10 years
3.21
Extreme 3.21
27.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 20-01-31
Director of Finance/CFO 54 20-04-30
Chief Tech/Sci/R&D Officer 38 13-12-31
Members of the board TitleAgeSince
Chairman 63 19-03-06
Director/Board Member 59 20-10-13
Director/Board Member 70 20-10-13
More insiders
Date Price Change Volume
24-03-28 3.45 +1.47% 2 906
24-03-27 3.4 -1.45% 7,055
24-03-26 3.45 -6.25% 10,988
24-03-25 3.68 -3.66% 5,803
24-03-22 3.82 -1.29% 8,011

Delayed Quote Xetra, March 28, 2024 at 06:44 am EDT

More quotes
BRAIN Biotech AG, formerly known as BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company develops and brings to market biological ingredients for Nutrition & Health, SkinCare and Industrial BioSolutions. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.4 EUR
Average target price
10.98 EUR
Spread / Average Target
+222.79%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock BRAIN Biotech AG - Xetra